医药卫生临床如何选择B受体阻滞剂课件.pptVIP

下载本文档

3
0
约3.61万字
约 60页
2018-06-23 发布于贵州
举报
版权申诉

医药卫生临床如何选择B受体阻滞剂课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

医药卫生临床如何选择B受体阻滞剂课件

BPLTT: Blood Pressure Lowering Treatment Trialist Collaboration ASCOT Anglo-Scandinavian Cardiac Outcomes Trial Reference(s)：(a) J Hypertens 1998;16 Suppl 2:S212 (b) Lancet 2003;361:1149–58 (c) Lancet 2005;366:895–906 Disease：Hypertension Purpose：To assess and compare the effects on nonfatal MI and fatal coronary heart disease of a beta-blocker with or without a diuretic vs a calcium antagonist with or without an ACE inhibitor in hypertensive patients, and of atorvastatinvs placebo in hypertensive patients with dyslipidaemia. Study design: Antihypertensive arm: randomised, parallel-group, 2 × 2 factorial. Lipid-lowering arm: double-blind, placebo-controlled, 2 × 2 factorial Follow-up: 5 years or 1150 primary endpoints Patients: Antihypertensive arm: 19,257 patients (9639 amlopidine, 9618 atenolol), mean age 63 years, with BP?≥ 160/100 mm Hg untreated or?≥ 140/90 mm Hg treated and?≥ 3 of 11 specified cardiovascular risk factors Lipid-lowering arm: 10,305 patients (5168 atorvastatin, 5137 placebo), with total blood cholesterol?≤ 6.5 mmol/l and a total cholesterol to HDL cholesterol ratio?≤ 4.5 Treatment regimen: Antihypertensive arm: atenolol with or without a diuretic, or amlodipine with or without an ACE inhibitor, titrated to target BP 140/90 mm Hg. Lipid lowering arm: atorvastatin, 10 mg/day, or placebo.Concomitant therapy: Doxazosin GITS at the discretion of the physicianResults: Antihypertensive arm: primary events of nonfatal MI plus fatal coronary heart disease occurred in 4.5% of patients in the amlodipine group compared to 4.9% of patients in the atenolol group (hazard ratio 0.90, 95% CI 0.79?1.02; p = 0.1052) Lipid-lowering arm: primary events of nonfatal MI plus fatal coronary heart disease occurred in 1.9% of patients in the atorvastatin group compared to 3.0% in the placebo group (hazard ratio 0.64, 95% CI 0.50?0.83; p = 0.0005) ALLHAT Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial Reference(s): (a) Am J Hypertens 1996;9